Home / Poster / APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTION OF CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDIs) INVOLVING ETHINYLESTRADIOL (EE)

Poster

APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTION OF CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDIs) INVOLVING ETHINYLESTRADIOL (EE)

APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTION OF CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDIs) INVOLVING ETHINYLESTRADIOL (EE)

Recommended for you

The Medicine Maker: The Biosimulation Generation

How Model-informed drug development rescue projects from a risky situation

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

On-Demand Webinar

© 2025 Certara. All Rights Reserved. | Privacy policy